Email Updates

Search form

You are here

PrEPVacc

Status
Planned
Phase
III
IIb
Principal Investigator(s)
Prof. Jonathan Weber
Objective

A combination effect study in Africa of two DNA-MVA- or DNA- Env protein HIV-1 vaccine regimens with pre-exposure prophylaxis (PrEP)

Prevention Option(s)
HIV Vaccine
PrEP
Arms and Assigned Interventions
Products
DNA
MVA
Protein
TDF
November 2019
December 2022
Enrollment
1 688
Sites

MRC/UVRI Uganda Research Unit on AIDS

Masaka
Uganda

Site(s) - Mozambique

Mozambique

Site(s) - South Africa

South Africa

Site(s) - Tanzania

United Republic of Tanzania